Payment overview · 2025
General Payments
$1,349.73
72 reported records · 20 companies
Healthcare provider profile · identity verified
Corey G. Albritton, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · DELHI, LA · NPI 1457322273
Verified facts
What the public records show
CMS Open Payments records show Corey G. Albritton, M.D. received $1,349.73 in general payments during 2025 across 72 reported records.
AstraZeneca Pharmaceuticals LP accounted for 13.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 35 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Farxiga, Jardiance, Kerendia, Linzess, Mounjaro, Ozempic, Rexulti, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 135 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 192 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Lokelma by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 160 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 121 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 121 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 230 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Rexulti by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 138 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 418 claims for Eliquis by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO as an associated drug or biological on 28 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Austedo by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $184.13 | 13.6% | 8 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $182.06 | 13.5% | 11 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $146.43 | 10.8% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $136.90 | 10.1% | 9 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $120.85 | 8.9% | 5 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $101.91 | 7.5% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $85.01 | 6.3% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $68.51 | 5.1% | 4 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $67.97 | 5.0% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $49.49 | 3.7% | 3 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $35.53 | 2.6% | 3 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $29.76 | 2.2% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $29.50 | 2.2% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $17.61 | 1.3% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.37 | 1.3% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $16.94 | 1.3% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $16.62 | 1.2% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $14.84 | 1.1% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.17 | 1.1% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $14.13 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,349.73 | 72 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $155.71 | 6 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $153.52 | 9 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $153.52 | 9 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $150.35 | 7 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $146.43 | 4 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $136.90 | 9 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $101.91 | 5 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $86.57 | 3 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $67.97 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $58.15 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $53.27 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $53.27 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $37.93 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $35.94 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $35.53 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $31.85 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $30.92 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $30.92 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $29.76 | 2 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $29.76 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $28.54 | 2 | 2025 |
Source payment records
|
|||||
| AVYCAZ Normalized: avycaz |
Drug | ABBVIE INC. | $18.02 | 1 | 2025 |
Source payment records
|
|||||
| DALVANCE Normalized: dalvance |
Drug | ABBVIE INC. | $18.02 | 1 | 2025 |
Source payment records
|
|||||
| TEFLARO Normalized: teflaro |
Drug | ABBVIE INC. | $18.02 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $17.61 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $17.61 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $16.94 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $16.62 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $15.92 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $15.00 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $14.84 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.17 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $14.13 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $13.72 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $13.72 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 192 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 121 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 160 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 135 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 230 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 138 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 42 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
135 | 31 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
58 | 15 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
192 | 33 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
160 | 23 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
121 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
121 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
230 | 30 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
74 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
138 | 26 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
418 | 55 |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 15 recipient NPIs · example record 1247249192 |
Austedo · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 932 | 163 |
| Levothyroxine Sodium | Levothyroxine Sodium | 760 | 128 |
| Gabapentin | Gabapentin | 668 | 108 |
| Pantoprazole Sodium | Pantoprazole Sodium | 578 | 103 |
| Losartan Potassium | Losartan Potassium | 533 | 103 |
| Furosemide | Furosemide | 531 | 105 |
| Amlodipine Besylate | Amlodipine Besylate | 512 | 102 |
| Metoprolol Succinate | Metoprolol Succinate | 484 | 91 |
| Eliquis | Apixaban | 418 | 55 |
| Potassium Chloride | Potassium Chloride | 397 | 66 |
| Omeprazole | Omeprazole | 346 | 68 |
| Tamsulosin Hcl | Tamsulosin Hcl | 344 | 58 |
| Clopidogrel | Clopidogrel Bisulfate | 333 | 55 |
| Lisinopril | Lisinopril | 289 | 59 |
| Ezetimibe | Ezetimibe | 288 | 46 |
| Metformin Hcl | Metformin Hcl | 283 | 51 |
| Donepezil Hcl | Donepezil Hcl | 268 | 42 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 256 | 51 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 244 | 48 |
| Hydralazine Hcl | Hydralazine Hcl | 242 | 42 |
| Allopurinol | Allopurinol | 237 | 43 |
| Topiramate | Topiramate | 231 | 30 |
| Mounjaro | Tirzepatide | 230 | 30 |
| Carvedilol | Carvedilol | 215 | 30 |
| Tramadol Hcl | Tramadol Hcl | 214 | 55 |
| Duloxetine Hcl | Duloxetine Hcl | 210 | 34 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 208 | 43 |
| Famotidine | Famotidine | 205 | 34 |
| Pravastatin Sodium | Pravastatin Sodium | 203 | 37 |
| Finasteride | Finasteride | 194 | 30 |
| Farxiga | Dapagliflozin Propanediol | 192 | 33 |
| Nifedipine Er | Nifedipine | 186 | 27 |
| Trazodone Hcl | Trazodone Hcl | 186 | 35 |
| Alendronate Sodium | Alendronate Sodium | 182 | 42 |
| Celecoxib | Celecoxib | 169 | 45 |
| Memantine Hcl | Memantine Hcl | 165 | 25 |
| Escitalopram Oxalate | Escitalopram Oxalate | 164 | 34 |
| Hydrochlorothiazide | Hydrochlorothiazide | 161 | 31 |
| Meloxicam | Meloxicam | 161 | 40 |
| Kerendia | Finerenone | 160 | 23 |
| Doxazosin Mesylate | Doxazosin Mesylate | 154 | 26 |
| Simvastatin | Simvastatin | 150 | 24 |
| Metoprolol Tartrate | Metoprolol Tartrate | 146 | 29 |
| Glimepiride | Glimepiride | 138 | 24 |
| Ozempic | Semaglutide | 138 | 26 |
| Fluticasone Propionate | Fluticasone Propionate | 135 | 34 |
| Linzess | Linaclotide | 135 | 31 |
| Buspirone Hcl | Buspirone Hcl | 125 | 21 |
| Sertraline Hcl | Sertraline Hcl | 122 | 20 |
| Alprazolam | Alprazolam | 121 | 20 |
| Jardiance | Empagliflozin | 121 | 17 |
| Diclofenac Sodium | Diclofenac Sodium | 117 | 22 |
| Spironolactone | Spironolactone | 116 | 20 |
| Metformin Hcl Er | Metformin Hcl | 112 | 20 |
| Methylprednisolone | Methylprednisolone | 112 | 90 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 110 | 22 |
| Tizanidine Hcl | Tizanidine Hcl | 108 | 20 |
| Pregabalin | Pregabalin | 92 | 13 |
| Mirtazapine | Mirtazapine | 90 | 11 |
| Prednisone | Prednisone | 87 | 47 |
| Montelukast Sodium | Montelukast Sodium | 86 | 16 |
| Glipizide | Glipizide | 85 | 13 |
| Azithromycin | Azithromycin | 83 | 74 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 82 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 78 | 14 |
| Amiodarone Hcl | Amiodarone Hcl | 77 | 16 |
| Entresto | Sacubitril/Valsartan | 74 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 73 | 13 |
| Atenolol | Atenolol | 71 | suppressed |
| Xarelto | Rivaroxaban | 69 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 66 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 65 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 65 | 51 |
| Doxycycline Hyclate | Doxycycline Hyclate | 65 | 51 |
| Clonazepam | Clonazepam | 64 | suppressed |
| Lorazepam | Lorazepam | 64 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 64 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 64 | 19 |
| Meclizine Hcl | Meclizine Hcl | 62 | 27 |
| Bupropion Xl | Bupropion Hcl | 60 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 60 | 22 |
| Myrbetriq | Mirabegron | 58 | 15 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 57 | 31 |
| Cefuroxime | Cefuroxime Axetil | 56 | 43 |
| Clonidine | Clonidine | 55 | suppressed |
| Irbesartan | Irbesartan | 54 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 54 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 54 | 20 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 53 | 12 |
| Levetiracetam | Levetiracetam | 52 | suppressed |
| Phenobarbital | Phenobarbital | 51 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 50 | suppressed |
| Rivastigmine | Rivastigmine | 50 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 49 | suppressed |
| Sotalol | Sotalol Hcl | 49 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 47 | suppressed |
| Austedo | Deutetrabenazine | 46 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 46 | suppressed |
| Estradiol | Estradiol | 45 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 45 | 11 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 45 | 34 |
| Repatha Sureclick | Evolocumab | 43 | suppressed |
| Cilostazol | Cilostazol | 42 | suppressed |
| Lactulose | Lactulose | 42 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 42 | suppressed |
| Rexulti | Brexpiprazole | 42 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 40 | suppressed |
| Januvia | Sitagliptin Phosphate | 39 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 39 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 38 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 38 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 37 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 36 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 36 | suppressed |
| Novolin R | Insulin Regular, Human | 36 | suppressed |
| Ondansetron Odt | Ondansetron | 36 | 19 |
| Digoxin | Digoxin | 35 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 35 | suppressed |
| Synthroid | Levothyroxine Sodium | 35 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 34 | suppressed |
| Nateglinide | Nateglinide | 34 | suppressed |
| Ranolazine Er | Ranolazine | 34 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 34 | 23 |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 34 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 33 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 33 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 32 | suppressed |
| Methocarbamol | Methocarbamol | 32 | 11 |
| Raloxifene Hcl | Raloxifene Hcl | 32 | suppressed |
| Vascepa | Icosapent Ethyl | 32 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 31 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 31 | suppressed |
| Temazepam | Temazepam | 31 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 30 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 30 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 30 | suppressed |
| Primidone | Primidone | 30 | suppressed |
| Baclofen | Baclofen | 29 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 29 | suppressed |
| Lovastatin | Lovastatin | 29 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 29 | suppressed |
| Creon | Lipase/Protease/Amylase | 28 | suppressed |
| Metolazone | Metolazone | 28 | suppressed |
| Timolol Maleate | Timolol Maleate | 28 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 27 | suppressed |
| Nystatin | Nystatin | 27 | 15 |
| Ventolin Hfa | Albuterol Sulfate | 27 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 26 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 26 | suppressed |
| Lamotrigine | Lamotrigine | 26 | suppressed |
| Tradjenta | Linagliptin | 26 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 25 | 21 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 25 | 14 |
| Fluconazole | Fluconazole | 25 | 20 |
| Trulicity | Dulaglutide | 24 | suppressed |
| Acarbose | Acarbose | 23 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 22 | suppressed |
| Colchicine | Colchicine | 22 | 16 |
| Enalapril Maleate | Enalapril Maleate | 21 | suppressed |
| Trimethoprim | Trimethoprim | 21 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 20 | suppressed |
| Ingrezza | Valbenazine Tosylate | 20 | suppressed |
| Olanzapine | Olanzapine | 20 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 19 | suppressed |
| Ibuprofen | Ibuprofen | 19 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 19 | suppressed |
| Nabumetone | Nabumetone | 19 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 19 | suppressed |
| Rybelsus | Semaglutide | 19 | suppressed |
| Sucralfate | Sucralfate | 19 | 14 |
| Valacyclovir | Valacyclovir Hcl | 19 | 13 |
| Cephalexin | Cephalexin | 18 | 14 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 18 | suppressed |
| Ketoconazole | Ketoconazole | 18 | suppressed |
| Nitroglycerin | Nitroglycerin | 18 | 14 |
| Terazosin Hcl | Terazosin Hcl | 18 | suppressed |
| Eszopiclone | Eszopiclone | 17 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 17 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 17 | suppressed |
| Calcitriol | Calcitriol | 16 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 16 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 16 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 15 | suppressed |
| Lansoprazole | Lansoprazole | 15 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 15 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 15 | suppressed |
| Amoxicillin | Amoxicillin | 14 | 14 |
| Colesevelam Hcl | Colesevelam Hcl | 14 | suppressed |
| Metronidazole | Metronidazole | 14 | 14 |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 14 | suppressed |
| Peg-3350 And Electrolytes | Peg3350/Sod Sulf,bicarb,cl/Kcl | 14 | 14 |
| Rivastigmine | Rivastigmine Tartrate | 14 | suppressed |
| Scopolamine | Scopolamine | 14 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 14 | suppressed |
| Amiloride Hcl | Amiloride Hcl | 13 | suppressed |
| Azathioprine | Azathioprine | 13 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 13 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 13 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 13 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 12 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Dutasteride | Dutasteride | 12 | suppressed |
| Glyburide Micronized | Glyburide,micronized | 12 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 12 | suppressed |
| Mirabegron Er | Mirabegron | 12 | suppressed |
| Perindopril Erbumine | Perindopril Erbumine | 12 | suppressed |
| Silodosin | Silodosin | 12 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Lacosamide | Lacosamide | 11 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 11 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 11 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,349.73 · 72 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AUSTEDO XR, AVYCAZ, BREZTRI, CAPVAXIVE, CREON, Cologuard Collection Kit, DALVANCE, EVENITY, FARXIGA, GARDASIL 9, GEMTESA, IBSRELA, JARDIANCE, Kerendia, LEQVIO, LINZESS, Leqembi, MOUNJARO, NEXLETOL, NURTEC ODT, OTEZLA, Ozempic, QULIPTA, REPATHA, REXULTI, Rybelsus, TEFLARO, UBRELVY, VAXNEUVANCE, VOQUEZNA, Veozah, Wegovy, ZAVZPRET, ZEPBOUND | 18 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error